Universal Beteiligungs und Servicegesellschaft mbH Sells 199,395 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,564,719 shares of the biopharmaceutical company's stock after selling 199,395 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Bristol Myers Squibb worth $95,432,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BMY. Thoroughbred Financial Services LLC increased its holdings in Bristol Myers Squibb by 1.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 190 shares during the last quarter. Marcum Wealth LLC grew its position in shares of Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock valued at $1,177,000 after acquiring an additional 193 shares during the period. Providence Capital Advisors LLC grew its position in shares of Bristol Myers Squibb by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 52,480 shares of the biopharmaceutical company's stock valued at $2,968,000 after acquiring an additional 221 shares during the period. Nemes Rush Group LLC grew its position in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. Nemes Rush Group LLC now owns 27,027 shares of the biopharmaceutical company's stock valued at $1,529,000 after acquiring an additional 221 shares during the period. Finally, 1858 Wealth Management LLC grew its position in shares of Bristol Myers Squibb by 3.6% in the 1st quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock valued at $392,000 after acquiring an additional 221 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.09% of the company's stock.

Bristol Myers Squibb Stock Performance

NYSE BMY traded up $0.01 during trading on Thursday, reaching $48.99. The company's stock had a trading volume of 4,679,306 shares, compared to its average volume of 13,342,394. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The firm has a market capitalization of $99.69 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 2.51 and a beta of 0.36. Bristol Myers Squibb Company has a 12 month low of $44.00 and a 12 month high of $63.33. The firm has a 50 day moving average price of $47.57 and a 200 day moving average price of $52.76.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the firm posted ($4.40) EPS. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.06%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BMY. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Jefferies Financial Group decreased their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus target price of $58.53.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.